📰 Alvr News
Page 4 - Alvr News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alvr. Real-time updates on events, politics, business and more.
April 22, 2023
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 8,408 shares of the firm’s stock in a transaction on Wednesday, April 19th. The shares were sold at an average price of $3.71, for a total value of $31,193.68. Following the transaction, the chief executive officer now owns 921,164 shares of the company’s stock, valued […]
April 21, 2023
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 8,408 shares of the stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $3.71, for a total transaction of $31,193.68. Following the transaction, the chief executive officer now owns 921,164 shares in the company, valued at $3,417,518.44. […]
April 4, 2023
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 5,790,000 shares, an increase of 6.8% from the February 28th total of 5,420,000 shares. Based on an average daily trading volume, of 275,300 shares, the […]
April 4, 2023
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 5,790,000 shares, a growth of 6.8% from the February 28th total of 5,420,000 shares. Based on an average trading volume of 275,300 shares, the short-interest […]
April 1, 2023
AlloVir (NASDAQ:ALVR – Get Rating) and Gilead Sciences (NASDAQ:GILD – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability. Institutional & Insider Ownership 78.7% of Gilead Sciences shares are owned […]
May 18, 2022
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) insider Beek Jeroen B. Van sold 15,262 shares of the stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $4.40, for a total value of $67,152.80. Following the completion of the transaction, the insider now directly owns 389,526 shares in the […]
May 10, 2022
AlloVir (NASDAQ:ALVR – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in […]
March 26, 2022
Zacks Investment Research upgraded shares of AlloVir (NASDAQ:ALVR – Get Rating) from a sell rating to a hold rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, “AlloVir, Inc. is a late clinical-stage cell therapy company which focus on restoring natural immunity against life-threatening viral diseases. AlloVir, Inc. is based in […]